Emerging New Agents in Diabetic Kidney Disease
(Julia Lewis, MD. ASN Renal Week 2005).
There are at least five new approaches beyond ACE inibitors to diabetic nephropathy: Aldosterone blockers, ruboxistaurin, prifenidone, COX-2 inhibition, and sulodexide. What is the
rationale for each of these interventions and what do the early pilot studies show?
(more...)
|
Coronary Angioplasty and Stenting: Indications and Results
(Mark Williams, MD. ASN Renal Week 2005). In diabetics mortality with CAD is increased and classically they do worse with percutaneous interventions due to restenosis rathen than with bypass surgery.
Is this also true for diabetic patients with CKD? To what extent has the picture changed with the use of drug-eluting stents? What are the anti-thrombotic strategies that can be used in such
patients after stenting and
how do these influence outcomes?
(more...)
|
The Role of Glycemic Control and How Best to Achieve it
(ASN Renal Week Clinical Nephrology Conference November, 2005, Philadelphia, PA)
To what extent does HbA1c predict adverse events in diabetics? In non-diabetics? How low must one go to avoid the increased CV risk? Is <7.0% low enough? What did follow-up from the DCCT/EDIC trials show? What is the benefit of multiple risk factor reduction (Steno-2 Trial)? What is the modern approach to glucose control, including use of metformin (in non-CKD), alpha-glucosidase inhibitors, incretins, secretagogues, and thiazolidinediones? What are practical points regarding use of PPAR-gamma agonists, exenatide? What are the benefits of the thiazolidinediones in terms of lipids, prevention of restenosis, and reduction of albuminuria?
(more...)
|
|
|
 |
|
Emerging New Agents in Diabetic Kidney Disease (Lewis) ASN 2005 Renal Week
|
|
|
Coronary Angioplasty and Stenting: Indications and Results (Williams) ASN 2005 Renal Week
|
|
Disease Management Actually Works in Dialysis Patients
(Sands)
RRI 2006, Part 2 (handouts)
|
|
|
Optimizing the Total Care of the Diabetic Patient with Kidney Disease - Lipids
(Molitch)
ASN Renal Week 2005
|
|
|
Optimizing the Total Care of the Diabetic with Kidney Disease
(McGill, Kaplan, Molitch, Williams)
ASN Renal Week 2005 (audiofiles)
|
|
|
Obesity and the Kidney
(Lord, Scherer, Fliser)
ASN Renal Week 2005 (audiofiles)
|
|
|
Novel Pathways for Prevention of Diabetes and Obesity-Related Renal and Vascular Disease
(Cooper, Danesh)
ASN Renal Week 2005 (audiofiles)
|
|
|
Newer Approaches to Diabetic Kidney Disease
(Hollenberg, Lewis, Pavlakis)
ASN Renal Week 2005 (audiofiles)
|
|
|
Diabetes and Dialysis
(Oreopoulos, Friedman, Dasgupta, Kopple)
ADC 2005 (audiofiles)
|
|
The Metabolic Syndrome and Kidney Disease: An Important Complication of Systemic Vascular Disease
(Tuttle)
ASN 2004
|
|
|
New Insights in the Pathogenesis of Uric Acid Nephrolithiasis
(Sakhaee)
ASN 2004
|
|
 |
|
Intensive versus moderate blood-pressure control in normotensive patients with type 2 diabetes (Briggs J) NCPN Jun 07
|
|
|
Hypomagnesemia in patients with type 2 diabetes CJASN 03-07
|
|
|
KDOQI Clinical Practice Guidelines and CPRs (2006 update) for Treatment of Diabetes and CKD AJKD (Feb 07)
|
|
|
(2006 Pharma )Year in Review (Michele B. Kaufman, PharmD, RPh) Dial-Transplant 12-06
|
|
|
ACE2: A new target for prevention of diabetic nephropathy? (Ingelfinger JR, commenting on an article by Batlle's group) JASN 11-06
|
|
|
Advanced glycation end products and nephrotoxicity of high-protein diets (Uribarri, Tuttle) CJASN 11-06
|
|
|
Angiotensin-converting enzyme-2 (ACE-2) - a new player in the genesis of glomerular injury? (Comment by Ritz on paper by Oudit et al) JASN 10-06
|
|
|
Management of dyslipidemias in patients with diabetes and chronic kidney disease (Molitch). CJASN 09-06
|
|
|
|
|
|
KDOQI
|
|
Diabetes Links
|
|
|
|
HDCN
Topic Pages (KEY)
|
|
|
|
|
 |
|
|
|
|
